{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T12:26:35Z","timestamp":1648643195444},"reference-count":66,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.lpm.2016.02.006","type":"journal-article","created":{"date-parts":[[2016,3,19]],"date-time":"2016-03-19T10:59:13Z","timestamp":1458385153000},"page":"495-508","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Infection par le virus de l\u2019h\u00e9patite C\u00a0: prise en charge th\u00e9rapeutique"],"prefix":"10.1016","volume":"45","author":[{"given":"Thierno","family":"Diatta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Chavade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Degos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"d\u2019Andon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lo\u00efc","family":"Guillevin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2016.02.006_bib0335","series-title":"H\u00e9patite C. Transmission nosocomiale. \u00c9tat de sant\u00e9 et devenir des personnes atteintes","author":"Institut national de la sant\u00e9 et de la recherche m\u00e9dicale","year":"2003"},{"key":"10.1016\/j.lpm.2016.02.006_bib0340","series-title":"Prise en charge des personnes infect\u00e9es par les virus de l\u2019h\u00e9patite B ou de l\u2019h\u00e9patite C. Rapport de recommandations","author":"Dhumeaux","year":"2014"},{"key":"10.1016\/j.lpm.2016.02.006_bib0345","series-title":"Hepatitis C","author":"World Health Organization","year":"2014"},{"issue":"1","key":"10.1016\/j.lpm.2016.02.006_bib0350","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0168-8278(00)80419-5","article-title":"Pathogenesis, diagnosis and management of hepatitis C","volume":"32","author":"Boyer","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.lpm.2016.02.006_bib0355","series-title":"EASL recommendations on treatment of hepatitis C","author":"European Association for the Study of the Liver","year":"2014"},{"key":"10.1016\/j.lpm.2016.02.006_bib0360","series-title":"Pr\u00e9valence des h\u00e9patites B et C en France en 2004","author":"Institut de veille sanitaire","year":"2007"},{"key":"10.1016\/j.lpm.2016.02.006_bib0365","series-title":"Plan national de lutte contre les h\u00e9patites B et C 2009\u20132012","author":"Minist\u00e8re de la sant\u00e9 et des sports","year":"2009"},{"issue":"1","key":"10.1016\/j.lpm.2016.02.006_bib0370","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7\u00a0genotypes and 67\u00a0subtypes: updated criteria and genotype assignment web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.lpm.2016.02.006_bib0375","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0808010","article-title":"Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection","volume":"361","author":"McHutchison","year":"2009","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.lpm.2016.02.006_bib0380","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.lpm.2016.02.006_bib0385","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.lpm.2016.02.006_bib0390","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1\u00a0infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.lpm.2016.02.006_bib0395","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1\u00a0infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.lpm.2016.02.006_bib0400","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"issue":"9941","key":"10.1016\/j.lpm.2016.02.006_bib0405","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","article-title":"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1\u00a0infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"384","author":"Jacobson","year":"2014","journal-title":"Lancet"},{"issue":"9941","key":"10.1016\/j.lpm.2016.02.006_bib0410","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","article-title":"Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1\u00a0infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3\u00a0trial","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.lpm.2016.02.006_bib0415","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2014.02.051","article-title":"Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1\u00a0who relapsed after previous therapy: a phase 3\u00a0trial","volume":"146","author":"Forns","year":"2014","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.lpm.2016.02.006_bib0420","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(14)71002-3","article-title":"Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1\u00a0infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3\u00a0trial","volume":"15","author":"Reddy","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.lpm.2016.02.006_bib0425","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jhep.2014.12.031","article-title":"Efficacy and safety of simeprevir with PegIFN\/ribavirin in naive or experienced patients infected with chronic HCV genotype 4","volume":"62","author":"Moreno","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.lpm.2016.02.006_bib0430","series-title":"SOVALDI 400mg, comprim\u00e9s pellicul\u00e9s. Bo\u00eete de 28 (CIP\u00a0: 34009 277 070 7 0). Avis de la Commission de la transparence du 14\u00a0mai 2014","author":"Haute Autorit\u00e9 de sant\u00e9","year":"2014"},{"issue":"20","key":"10.1016\/j.lpm.2016.02.006_bib0435","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2\u00a0or 3\u00a0in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.lpm.2016.02.006_bib0440","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2\u00a0and 3","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.lpm.2016.02.006_bib0445","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/hep.27567","article-title":"Sofosbuvir with peginterferon-ribavirin for 12\u00a0weeks in previously treated patients with hepatitis C genotype 2\u00a0or 3\u00a0and cirrhosis","volume":"61","author":"Lawitz","year":"2015","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.lpm.2016.02.006_bib0450","first-page":"256","article-title":"LO5: Sofosbuvir+peginterferon\/ribavirin for 12\u00a0weeks vs sofosbuvir+ribavirin for 16\u00a0or 24\u00a0weeks in genotype 3\u00a0HCV infected patients and treatment-experienced cirrhotic patients with genotype 2\u00a0HCV: The boson study","volume":"62","author":"Foster","year":"2015","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.lpm.2016.02.006_bib0455","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jama.2014.7734","article-title":"Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection","volume":"312","author":"Sulkowski","year":"2014","journal-title":"JAMA"},{"issue":"9973","key":"10.1016\/j.lpm.2016.02.006_bib0460","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S0140-6736(14)62483-1","article-title":"Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3\u00a0study","volume":"385","author":"Molina","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.lpm.2016.02.006_bib0465","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2014.09.023","article-title":"Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study","volume":"148","author":"Curry","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lpm.2016.02.006_bib0470","series-title":"OLYSIO 150mg, g\u00e9lules. Bo\u00eete de 7 (CIP\u00a0: 34009 2788558 7). Bo\u00eete de 28 (CIP\u00a0: 34009 2788564 8). Avis de la Commission de la transparence du 17\u00a0d\u00e9cembre 2014","author":"Haute Autorit\u00e9 de sant\u00e9","year":"2014"},{"issue":"9956","key":"10.1016\/j.lpm.2016.02.006_bib0475","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1\u00a0in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.lpm.2016.02.006_bib0480","doi-asserted-by":"crossref","first-page":"S270","DOI":"10.1016\/S0168-8278(15)30168-9","article-title":"A phase-3, randomised, open-label study to evaluate the efficacy and safety of 8\u00a0and 12\u00a0weeks of Simeprevir (SMV) plus Sofosbuvir (SOF) in treatment-naive and -experienced patients with chronic HCV genotype 1\u00a0infection without cirrhosis: Optimist-1","volume":"62","author":"Kwo","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.lpm.2016.02.006_bib0485","doi-asserted-by":"crossref","DOI":"10.1002\/hep.28422","article-title":"Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1\u00a0infection and cirrhosis: a phase 3\u00a0study (OPTIMIST-2)","author":"Lawitz","year":"2015","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.lpm.2016.02.006_bib0490","first-page":"220A","article-title":"Evaluation of Sofosbuvir and Simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population","volume":"60","author":"Dieterich","year":"2014","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.lpm.2016.02.006_bib0495","first-page":"219A","article-title":"Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real-world experience in a diverse, longitudinal observational cohort","volume":"60","author":"Jensen","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.lpm.2016.02.006_bib0500","series-title":"DAKLINZA 30mg, comprim\u00e9 pellicul\u00e9. B\/28 (CIP\u00a0: 3400927941160). B\/28 (CIP\u00a0: 3400927941221). DAKLINZA 60mg, comprim\u00e9 pellicul\u00e9. B\/28 (CIP\u00a0: 3400927941399). B\/28 (CIP\u00a0: 3400927941450). Avis de la Commission de la transparence du 17\u00a0d\u00e9cembre 2014","author":"Haute Autorit\u00e9 de sant\u00e9","year":"2014"},{"issue":"3","key":"10.1016\/j.lpm.2016.02.006_bib0505","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.lpm.2016.02.006_bib0510","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3\u00a0infection: ALLY-3\u00a0phase III study","volume":"61","author":"Nelson","year":"2015","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.lpm.2016.02.006_bib0515","doi-asserted-by":"crossref","first-page":"S258","DOI":"10.1016\/S0168-8278(15)30149-5","article-title":"Safety and efficacy of the combination Daclatasvir sofosbuvir in HCV genotype 1-mono-infected patients from the French Observational cohort ANRS CO22","volume":"62","author":"Pol","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.lpm.2016.02.006_bib0520","series-title":"The International Liver Congress 2015-50th annual Meeting of the European association for the Study of the Liver","article-title":"Daclatasvir Plus Sofosbuvir for Treatment of HCV Genotypes 1-4\u00a0in HIV-HCV Coinfection: The ALLY-2\u00a0Study","author":"Wyles","year":"2015"},{"key":"10.1016\/j.lpm.2016.02.006_bib0525","series-title":"HARVONI 90mg\/400mg, comprim\u00e9s pellicul\u00e9s. B\/28 (CIP\u00a0: 34009 300 008 8 5). Avis de la Commission de la transparence du 4\u00a0mars 2015","author":"Haute Autorit\u00e9 de sant\u00e9","year":"2015"},{"issue":"20","key":"10.1016\/j.lpm.2016.02.006_bib0530","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1\u00a0infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.lpm.2016.02.006_bib0535","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8\u00a0or 12\u00a0weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.lpm.2016.02.006_bib0540","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1\u00a0infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.lpm.2016.02.006_bib0545","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jama.2015.1373","article-title":"Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1\u00a0and HIV co-infection","volume":"313","author":"Osinusi","year":"2015","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.lpm.2016.02.006_bib0550","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","article-title":"Ledipasvir and Sofosbuvir plus Ribavirin for treatment of HCV infection in patients with advanced liver disease","volume":"149","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lpm.2016.02.006_bib0555","series-title":"VIEKIRAX 12,5mg\/75mg\/50mg, comprim\u00e9 pellicul\u00e9. B\/56 (CIP\u00a0: 34009 300 078 0 8). Avis de la Commission de la transparence du 17\u00a0d\u00e9cembre 2014","author":"Haute Autorit\u00e9 de sant\u00e9","year":"2014"},{"issue":"17","key":"10.1016\/j.lpm.2016.02.006_bib0560","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Feld","year":"2014","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.lpm.2016.02.006_bib0565","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"Ferenci","year":"2014","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.lpm.2016.02.006_bib0570","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","article-title":"Retreatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.lpm.2016.02.006_bib0575","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2014.04.045","article-title":"ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97\u00a0% and 100\u00a0% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection","volume":"147","author":"Andreone","year":"2014","journal-title":"Gastroenterology"},{"issue":"21","key":"10.1016\/j.lpm.2016.02.006_bib0580","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"Poordad","year":"2014","journal-title":"N Engl J Med"},{"issue":"9986","key":"10.1016\/j.lpm.2016.02.006_bib0585","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1016\/S0140-6736(15)60159-3","article-title":"Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4\u00a0chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial","volume":"385","author":"Hezode","year":"2015","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.lpm.2016.02.006_bib0590","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2015.1328","article-title":"Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial","volume":"313","author":"Sulkowski","year":"2015","journal-title":"JAMA"},{"issue":"25","key":"10.1016\/j.lpm.2016.02.006_bib0595","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMoa1408921","article-title":"An interferon-free antiviral regimen for HCV after liver transplantation","volume":"371","author":"Kwo","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.lpm.2016.02.006_bib0600","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/cid\/ciu675","article-title":"Simeprevir (TMC435) with pegylated interferon\/ribavirin in patients coinfected with HCV genotype 1\u00a0and HIV-1: a phase 3\u00a0study","volume":"59","author":"Dieterich","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lpm.2016.02.006_bib0605","series-title":"Viekirax, avec ou sans Exviera\u00a0: traitement non recommand\u00e9 chez les patients pr\u00e9sentant une insuffisance h\u00e9patique mod\u00e9r\u00e9e (stade Child-Pugh B)","author":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9","year":"2016"},{"key":"10.1016\/j.lpm.2016.02.006_bib0610","series-title":"Risque d\u2019arythmies cliniquement significatives avec Harvoni ou Sovaldi en association avec Daklinza lors de la co-administration avec l\u2019amiodarone","author":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9","year":"2016"},{"key":"10.1016\/j.lpm.2016.02.006_bib0615","series-title":"Recommandations AFEF sur la prise en charge des h\u00e9patites virales C","author":"Association fran\u00e7aise pour l\u2019\u00e9tude du foie","year":"2015"},{"issue":"1","key":"10.1016\/j.lpm.2016.02.006_bib0620","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL Recommendations on treatment of hepatitis C 2015","volume":"63","author":"Liver","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.lpm.2016.02.006_bib0625","series-title":"Prise en charge de l\u2019h\u00e9patite C par les m\u00e9dicaments anti-viraux \u00e0 action directe (AAD). Recommandation du Coll\u00e8ge","author":"Haute Autorit\u00e9 de sant\u00e9","year":"2014"},{"key":"10.1016\/j.lpm.2016.02.006_bib0630","article-title":"HCV genotype 3, hispanic ethnicity linked to higher risk of cirrhosis","author":"Highleyman","year":"2014","journal-title":"Liver Cancer"},{"issue":"1","key":"10.1016\/j.lpm.2016.02.006_bib0635","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/liv.12576","article-title":"Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis","volume":"35","author":"Akhtar","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.lpm.2016.02.006_bib0640","article-title":"Les manifestations extra-h\u00e9patiques au cours de l\u2019infection par le virus de l\u2019h\u00e9patite C","author":"S\u00e8ne","year":"2010"},{"key":"10.1016\/j.lpm.2016.02.006_bib0645","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6\u00a0infection","author":"Feld","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2016.02.006_bib0650","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and Velpatasvir for HCV genotype 2\u00a0and 3\u00a0infection","author":"Foster","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.lpm.2016.02.006_bib0655","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M15-0785","article-title":"Grazoprevir-Elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6\u00a0infection: a randomized trial","volume":"163","author":"Zeuzem","year":"2015","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.lpm.2016.02.006_bib0330","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1016\/S2352-3018(15)00114-9","article-title":"Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial","volume":"2","author":"Rockstroh","year":"2015","journal-title":"Lancet HIV"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498216000713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498216000713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T06:53:58Z","timestamp":1536908038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498216000713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0755498216000713"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2016.02.006","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infection par le virus de l\u2019h\u00e9patite C\u00a0: prise en charge th\u00e9rapeutique","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2016.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}